Prothena reported $6.99M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 1.57B 10.58M Sep/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amgen USD 57.3B 19M Jun/2026
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Exelixis USD 162.2M 3.73M Sep/2026
Immunic USD 0 0 Jun/2024
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
MacroGenics USD 35.09M 1.42M Jun/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Prothena USD 6.99M 663K Jun/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026